PatientIQ Raises $30M Series C for Outcomes Intelligence

Patient-reported outcomes can capture what a scan, billing code, or clinician note misses: whether treatment changed how a person actually lives. PatientIQ now has $30M to make that evidence easier to collect and use across care, research, and industry.

The Series C, announced September 3, 2026, was led by Hughes & Company. The Chicago healthcare-technology company says the financing will help it expand across health systems and medical specialties, grow its real-world-evidence business for medical-device and life-sciences organizations, and build a direct-to-patient commerce experience.

PatientIQ reports that its network now spans more than 870 healthcare organizations and over 17M patients, with more than 70M patient outcomes collected. Those figures describe company-reported scale, while the deeper test is whether the same infrastructure can keep the patient's voice intact as it moves into more specialties, more industry programs, and a new commerce layer.

What Happened

According to the Series C announcement, Hughes & Company led PatientIQ's $30M financing. Health Enterprise Partners and August Capital were named as current investors, and Travis Hughes, Hughes & Company's Founder and Managing Partner, will join PatientIQ's board. The announcement did not disclose a valuation or detailed financing terms.

PatientIQ previously announced a $20M Series B in May 2022, led by Health Enterprise Partners with August Capital participating. That gives the company at least $50M in publicly disclosed financing across its Series B and Series C. Earlier financings appear in secondary databases, but their amounts were not verified from primary sources, so a definitive lifetime total would overstate the available evidence.

PatientIQ's Outcomes Intelligence Platform

PatientIQ was founded in 2016 by Matthew Gitelis, who remains Founder and CEO. After beginning his career in investment banking, Gitelis entered medical school and conducted outcomes research, where he encountered the friction of extracting useful clinical information from fragmented systems. PatientIQ grew from that collision between financial analytics and healthcare's much more consequential data problem.

The company now sells 3 EHR-integrated product lines. ClinicalPRO supports routine patient-reported outcomes programs, ResearchPRO supports studies and registries, and DataPRO supports benchmarking and real-world-evidence analysis. PatientIQ says the broader platform integrates with more than 50 EHR systems, including Epic, Oracle Cerner, and athenahealth, and supports automated data collection across more than 20 medical specialties.

PatientIQ's value proposition depends less on the survey itself than on the handoffs around it. The platform must identify the appropriate patient, collect a response at a useful point in recovery, connect that response with the correct clinical record, and make the result available to clinicians, researchers, registry operators, or industry teams without creating another manual process.

Why Patient-Reported Outcomes Matter Now

Patient-reported outcomes capture symptoms, function, pain, mobility, and quality of life directly from patients. These measures can show whether treatment changed the patient's lived condition, including aspects of recovery that may not appear in an image, lab value, or billing record. Their usefulness depends on consistent collection and enough context to compare results across time and populations.

CMS describes patient-reported outcome measures as a way to measure symptoms, functional ability, and quality of life from the patient's perspective. Defined federal programs are also moving toward mandatory reporting and public performance results. That creates an operational burden for providers, but it also makes reliable outcomes infrastructure more strategically valuable.

The same data matters beyond health systems. Medical-device and life-sciences companies use real-world evidence for research, regulatory work, product differentiation, and post-market surveillance. PatientIQ reports that it supports national registries involving the American Academy of Orthopaedic Surgeons, the American Association of Neurological Surgeons, and the Society for Thoracic Surgeons.

What the Series C Will Fund

PatientIQ says it will use the financing to deepen adoption within existing specialties and health systems while expanding its real-world-evidence platform for medical-device and life-sciences companies. The company reports that its EHR-integrated network grew from 200 healthcare organizations at the time of the 2022 Series B to more than 870 today, while its patient population expanded to more than 17M.

The third priority is a direct-to-patient commerce experience that connects patients with products and services through a growing marketplace. That could extend PatientIQ from measurement and evidence into a transaction layer informed by recovery data. The company did not disclose a launch timetable, economics, or safeguards specific to that proposed offering, so the marketplace should be treated as a funded direction rather than a proven line of business.

The Trust Boundary Around Outcomes Data

PatientIQ's reported scale creates a useful data asset, but healthcare outcomes are valuable precisely because the underlying relationship is sensitive. A platform used by care teams, researchers, and patients must keep collection reliable, preserve privacy, and distinguish measurement from recommendation. The challenge grows as the same network serves providers, registries, medical-device companies, life-sciences organizations, and eventually commerce.

PatientIQ states that its platform maintains HITRUST CSF and SOC 2 Type II certifications. Its official materials also describe EHR-integrated workflows and a SMART on FHIR collaboration with Zimmer Biomet. Those capabilities explain how data may move through the system, but security credentials and integrations do not independently prove clinical improvement or commercial adoption.

What the Funding Signals for Healthcare Data

Hughes & Company's lead investment reflects a growth-equity thesis around healthcare software rather than a broad bet on consumer surveys. The firm spent a year studying the patient-reported outcomes category, according to Travis Hughes in the announcement, and is backing a company that reports a large provider network, a growing patient dataset, and multiple routes into provider and industry budgets.

For healthcare operators, the signal is that outcomes measurement is becoming infrastructure instead of an occasional research exercise. The valuable layer connects a patient's answer to the clinical, regulatory, and commercial decision that depends on it. PatientIQ's Series C gives the company more room to widen that connection, with the trust earned inside care still determining how far the network can travel.